Effect of age and vaccination status of the dam on the serological response of foals to vaccination with an activated rabies vaccine  by Wilson, W.D. & Edman, J.E.
Table 1
Vaccination schedule
Group # of
horses
1st vaccination
Week 0
2nd vaccination
Week 2
3rd vaccination
Week 6
1 3 1ml Vetera®
Gold + VEE
N/A N/A
2 3 0.2mg DIII 0.2mg DIII 0.2mg DIII
3 3 0.2mg DIII+T 0.2mg DIII+T 0.2mg DIII
4 3 0.2mg DIII-
CD40L
0.2mg DIII-
CD40L
0.2mg DIII-CD40L
5 3 0.2mg DIII-
CD40L+T
0.2mg DIII-
CD40L+T
0.2mg DIII-CD40L
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strength of evidence accrued, the time required and the costs
incurred. Segregation into smaller discrete groups is common to
all three approaches and is believed to be key to a successful
strategy through minimising the spread of disease through the
population and allowing clearance and release of quarantine
measures as soon as possible. The Gold tier option provides
insight into both the extent of recent infectious spread (based on
CFT serology) and current infectiousness (based on agent detec-
tion tests, especially PCR) in each segregated group while allow-
ing risk management to then be optimised speciﬁcally to each
group. This option also facilitates prompt removal to an isolation
area of infectious horses from segregated groups, so reducing
likelihood of ongoing infectious transmission within the group
and overall morbidity. The Silver tier option incurs fewer costs
than the Gold option as whole blood samples are not screened for
viraemia by virus isolation (qPCR is not optimised for this pur-
pose), but it only provides an insight into the extent of actively
shedding and exposed horses without detecting potentially in-
fectious viraemic animals. The Bronze tier option provides a
retrospective insight into the extent of infectious spread but relies
on observation of neurological signs and/or abortions/neonatal
foal deaths to trigger further investigations, thereby potentially
missing subclinical infectious spread, which is a recognised
phenomenon in propagating EHV-1 outbreaks. This option may
be the cheapest of the three with respect to laboratory costs but
the lack of initial information about the infectious status in all
segregated groups might ultimately lengthen the time for
effecting overall control of the outbreak and depending on how
many segregated groups are further investigated, may ultimately
not signiﬁcantly reduce laboratory costs.
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WestNile Virus (WNV), since its introduction in 1999, is endemic in
the US and causes severe neurologic disease in horses. There is no
effective pharmaceutical treatment for WNV infection, so vaccina-
tion is the only approach to prevention and control of disease. The
purpose of this study was to evaluate a recombinant vaccine con-
taining Domain III (DIII) of the WNV envelope glycoprotein with
and without a natural adjuvant CD-40L in producing virus
neutralizing antibodies in horses. Fifteen Thoroughbred horses
were randomly divided into ﬁve groups and were immunized per
the schedule in Table 1. Venous blood samples were collected from
each horse prior to vaccination, the 1 and 2 weeks after initial
vaccination, and biweekly thereafter to 16 weeks. Serum IgGa
concentration in horses vaccinated with the DIII-CD40L+TiterMax
and DIII-CD40L groups were increased after the second booster
vaccination and were signiﬁcantly (p<0.05) higher compared to
other groups. Serum IgGb and IgG(T) concentrations were not
signiﬁcantly increased during the experimental period among all
groups. Western blot results showed that DIII-CD40L protein (with
or without TiterMax) groups had the highest speciﬁc anti-DIII
antibody activities after vaccinations. Moreover, the groups
immunized with DIII-CD40L protein (with or without TiterMax)
showed stronger neutralization activity and were signiﬁcantly(p<0.05) higher compared to other groups starting from Week 8.
The results demonstrated that vaccinationwith recombinantWNV
E DIII-CD40L protein induced speciﬁc immune response in healthy
horses that might be protective against WNV-associated disease.
CD40L couldbeutilizedas anon-toxic, alternative adjuvant toboost
the immunogenicity of subunit vaccines in horses.T: TiterMax adjuvant was purchased from CytRx Corporation.
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Vaccination of domestic animal against rabies is important for
preventing this fatal infection, which in turn reduces the risk of
human exposure in rabies-endemic areas. These public health
concerns provided the main impetus for the American Associa-
tion of Equine Practitioners (AAEP) to include rabies as a core
vaccine for all horses in North America in its vaccination guide-
lines. The result is that a higher proportion of horses, including
broodmares, are now rabies antibody-positive, as are their foals
via passive transfer of maternally derived antibodies (MDA).
Current label recommendations for primary vaccination against
rabies include administration of one dose of inactivated vaccine at
three months of age or older, followed by a second dose at one
year of age. MDA has been shown to inhibit the response of three-
month-old foals to inactivated vaccines directed against several
important equine pathogens; however, the impact of MDA on the
response of foals to rabies vaccine has not previously being
investigated. The serologic response to two doses of an inacti-
vated rabies vaccine administered onemonth apart was evaluated
using the rapid ﬂorescent focus inhibition test (RFFIT) in three-
month-old and six-month-old foals born to rabies-vaccinated
mares. Foals from non-vaccinated mares served as antibody-
negative controls. Rabies antibodies were not detected in samples
collected before vaccination from foals born to non-vaccinated
mares. In contrast, high titers of antibody were present in post-
nursing samples from foals born to vaccinated mares. Titers
declined with a half-life of approximately 30 days; however,
rabies antibody was still detectable at six months of age in most
foals. Both three-month-old and six-month-old foals from non-
vaccinated mares mounted a substantial serolologic response
after administration of one dose of vaccine, and experienced a
further increase in titer after administration of the second dose
four weeks later. In contrast, MDAs present at the time of initial
vaccination completely blocked the response of three-month-old
foals from vaccinated mares to administration of two doses of
vaccine. The response of these foals to a third dose administered
at one year of age was much poorer than the response seen in
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failed to prime the immune response. Whereas six-month-old
foal from vaccinated mares did not typically show seroconversion
in response to one dose of vaccine, all mounted a measurable
response to the second dose. Based on the results of the study,
three-month-old foals from vaccinated mares may be left un-
protected if label directions for administration of a single dose as
early as 3 months of age are followed. Vaccination of foals of
rabies-vaccinated mares should be delayed until six months of
age or older and should include two doses of vaccine in the pri-
mary series, rather than the recommended one dose, in order to
consistently achieve satisfactory priming.
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West Nile virus (WNV) became an important arbovirus pathogen
for equines for the American continent since its introduction in
1999. However, a worldwide emergence as an equine pathogen is
shows form last 5 years. In Argentina, ﬁrst evidence of native
circulation was registered in 2004 in birds and 2006 in equines.
With the aim to corroborate the enzootic transmission of WNV in
its potential avian hosts we survey avian sera collected in rural
(Mar Chiquita lagoon) and urban (Cordoba city) areas of Cordoba
province. Sera collections were carried out in both places during
summer and fall in 2005 and 2012 (Mar Chiquita) and in 2005 and
2013 (Cordoba). WNV seroprevalence increased between years in
Cordoba (2.6% [2005] vs. 3.3% [2013]) and Mar Chiquita (2.8
[2005] vs. 3.7 [2012]). In Cordoba city 18 bird species were
detected infected being the most seroprevalence Cattle Tyrant
(Machetornis rixosus), Rufous Hornero (Furnarius rufus) and
Creamy-bellied Thrush (Turdus amaurochalinus). On the other
hand only 9 seropositive bird species were found in Mar Chiqui-
ta.Grassland Yellow-ﬁnch (Sicalis luteola), Picui ground dove
(Columbina picui) and Rufous Hornero (Furnarius rufus) were the
most found frequently infected. Our data suggest that WNV is
actively transmitted in urban and rural areas in the central region
of the province of Cordoba, using free ranging birds as potential
amplifying hosts. The exotic West Nile virus was introduced in
Argentina in 2004. Evidences support its wide dispersion and
successful establishment in the north and central region of the
country. However, neither massive bird mortality events nor
equine and human epidemic events were reported. There is no
evidence regarding this discrepancy with the United States.
Further ecological and virological studies are needed to elucidate
factors inﬂuencing its epidemiological behavior.
Posters
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are endemic in the US and cause neurologic disease in horses.
Diagnosis is based on clinical signs and a serum capture ELISA IgM
titer >1:400. Vaccination of horses and foals with WNV and EEE
vaccines might illicit an IgM antibody response that could inter-
fere with the capture ELISA diagnostic test, especially if horses
and foals are tested after vaccination. The hypothesis of this study
is horses and foals vaccinated with a multivalent vaccine con-
taining WN and EEE antigens will not elicit an IgM antibody
response of >1:400. Six adult horses (8e25 years) and six 4
month old pony foals and their dams were used in the study. Both
horses and foals were vaccinated with a commercially available
combination vaccine (Vetera® Gold, Boehringer Ingelheim Vet-
medica, St. Joseph, MO) containing killed WNV and EEE antigens.
Adult horses and dams of the ponies had a yearly history of
vaccination, whereas the pony foals had not been previously
vaccinated. Blood samples were collected from the jugular vein of
the horses, dams and foals on Days 0 (prior to vaccination), 7, 14,
and 21 days after the 1st vaccination. On day 21, foals were given a
booster vaccination and additional blood samples were obtained
days 7, 14 and 21 post booster vaccination. In addition, blood
samples were obtained from the foal’s dams at the same days and
were used as sentinels for virus exposure, as foals and dams were
housed together in a pasture. Blood samples were centrifuged and
serum collected and frozen at 80C until shipment. Serologic
assays for WNV and EEE, including IgM antibody capture ELISA
(MAC-ELISA) and Plaque Reduction Neutralization Assay (PRNT),
were performed at the National Veterinary Services Laboratory
(NVSL) in Ames, IA, USA.
All MAC-ELISA titers for WNV and EEE were negative at 1:400
for the horses, foals and foal’s dams during the study period. In
the adult horses, PRNT titers ranged from 1:10 to >1:100 for EEE
and was >1:100 for WNV at all days. In the pony foals, PRNT titers
to EEE and WNV ranged from negative to 1:10 prior to vaccine
administration to >1:100 after the second vaccination. One foal
had negative PRNT titers to EEE throughout the experiment.
Vaccination with a multivalent vaccine containing WNV and EEE
elicited an antibody response in horses and pony foals. However,
vaccination did not increase IgM titers >1:400, 7 days after
vaccination in the horses or ponies and after 2nd vaccination in
naïve pony foals. Therefore, vaccination does not interfere with
serologic testing for naturally occurring WNV and EEE infections.
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West Nile virus (WNV) is a neurotropic ﬂavivirus mainly trans-
mitted throughmosquito bites and whose reservoir hosts are wild
birds. Equids and humans are incidental dead end hosts and can
develop severe neurological symptoms in 1-10% cases. Despite
enhanced reporting ofWNV outbreaks in Europe during the past 5
years, much remains to be explored about the virulence level and
determinants of WNV strains circulating in Europe. Of note,
expanding lineage 2 virus has gained a proline residue at position
249 in the non-structural 3 (NS3) protein and has caused theworst
epidemics ever experienced in central and Southern Europe
(Greece, Serbia,…). Interestingly, Brault et al. (2007) identiﬁed
NS3249P as being crucial for the virulence of WNV in American
